Search

Author/Creator Cho, E. J.

1. Comparison of overall survival between antiviral‐induced viral suppression and inactive phase chronic hepatitis B patients. Issue 10 (24th May 2018)

Authors:
Cho, Y. Y.; Lee, J.‐H.; Chang, Y.; Nam, J. Y.; Cho, H.; Lee, D. H.; Cho, E. J.; Lee, D. H.; Yu, S. J.; Lee, J. M.; Kim, Y. J.; Yoon, J.‐H.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 10(2018)
Page Start:
1161
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg‐positive high viral load chronic hepatitis B. Issue 5 (14th March 2018)

Authors:
Nam, J. Y.; Chang, Y.; Cho, H.; Kang, S. H.; Cho, Y. Y.; Cho, E. J.; Lee, J.‐H.; Yu, S. J.; Yoon, J.‐H.; Kim, Y. J.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 5(2018)
Page Start:
552
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Entecavir and tenofovir reduce hepatitis B virus‐related hepatocellular carcinoma recurrence more effectively than other antivirals. Issue 6 (6th February 2018)

Authors:
Cho, H.; Ahn, H.; Lee, D. H.; Lee, J.‐H.; Jung, Y. J.; Chang, Y.; Nam, J. Y.; Cho, Y. Y.; Lee, D. H.; Cho, E. J.; Yu, S. J.; Lee, J. M.; Kim, Y. J.; Yoon, J.‐H.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 6(2018)
Page Start:
707
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B‐endemic area. Issue 11 (2nd April 2018)

Authors:
Kim, H. Y.; Nam, J. Y.; Lee, J.‐H.; Lee, H. A.; Chang, Y.; Lee, H. Y.; Cho, H.; Lee, D. H.; Cho, Y. Y.; Cho, E. J.; Yu, S. J.; Lee, J. M.; Kim, Y. J.; Yoon, J.‐H.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 11(2018)
Page Start:
1490
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Issue 9 (24th August 2017)

Authors:
Kang, S. H.; Lee, Y. B.; Lee, J.‐H.; Nam, J. Y.; Chang, Y.; Cho, H.; Yoo, J.‐J.; Cho, Y. Y.; Cho, E. J.; Yu, S. J.; Kim, M. Y.; Kim, Y. J.; Baik, S. K.; Yoon, J.‐H.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 46:Issue 9(2017)
Page Start:
845
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗